These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1197 related items for PubMed ID: 10496349

  • 1. Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system.
    Culig Z, Hoffmann J, Erdel M, Eder IE, Hobisch A, Hittmair A, Bartsch G, Utermann G, Schneider MR, Parczyk K, Klocker H.
    Br J Cancer; 1999 Sep; 81(2):242-51. PubMed ID: 10496349
    [Abstract] [Full Text] [Related]

  • 2. The androgen receptor pathway is by-passed in prostate cancer cells generated after prolonged treatment with bicalutamide.
    Hobisch A, Fritzer A, Comuzzi B, Fiechtl M, Malinowska K, Steiner H, Bartsch G, Culig Z.
    Prostate; 2006 Mar 01; 66(4):413-20. PubMed ID: 16302272
    [Abstract] [Full Text] [Related]

  • 3. Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome.
    Hara T, Miyazaki J, Araki H, Yamaoka M, Kanzaki N, Kusaka M, Miyamoto M.
    Cancer Res; 2003 Jan 01; 63(1):149-53. PubMed ID: 12517791
    [Abstract] [Full Text] [Related]

  • 4. Biological properties of androgen receptor pure antagonist for treatment of castration-resistant prostate cancer: optimization from lead compound to CH5137291.
    Kawata H, Arai S, Nakagawa T, Ishikura N, Nishimoto A, Yoshino H, Shiraishi T, Tachibana K, Nakamura R, Sato H.
    Prostate; 2011 Sep 01; 71(12):1344-56. PubMed ID: 21308717
    [Abstract] [Full Text] [Related]

  • 5. Antiandrogen bicalutamide promotes tumor growth in a novel androgen-dependent prostate cancer xenograft model derived from a bicalutamide-treated patient.
    Yoshida T, Kinoshita H, Segawa T, Nakamura E, Inoue T, Shimizu Y, Kamoto T, Ogawa O.
    Cancer Res; 2005 Nov 01; 65(21):9611-6. PubMed ID: 16266977
    [Abstract] [Full Text] [Related]

  • 6. Establishment and characterization of an androgen receptor-dependent, androgen-independent human prostate cancer cell line, LNCaP-CS10.
    Ishikura N, Kawata H, Nishimoto A, Nakamura R, Ishii N, Aoki Y.
    Prostate; 2010 Apr 01; 70(5):457-66. PubMed ID: 19902465
    [Abstract] [Full Text] [Related]

  • 7. Activity of androgen receptor antagonist bicalutamide in prostate cancer cells is independent of NCoR and SMRT corepressors.
    Hodgson MC, Astapova I, Hollenberg AN, Balk SP.
    Cancer Res; 2007 Sep 01; 67(17):8388-95. PubMed ID: 17804755
    [Abstract] [Full Text] [Related]

  • 8. Androgen receptor signaling and vitamin D receptor action in prostate cancer cells.
    Murthy S, Agoulnik IU, Weigel NL.
    Prostate; 2005 Sep 01; 64(4):362-72. PubMed ID: 15754350
    [Abstract] [Full Text] [Related]

  • 9. Phosphorylation/dephosphorylation of androgen receptor as a determinant of androgen agonistic or antagonistic activity.
    Wang LG, Liu XM, Kreis W, Budman DR.
    Biochem Biophys Res Commun; 1999 May 27; 259(1):21-8. PubMed ID: 10334909
    [Abstract] [Full Text] [Related]

  • 10. Ligand-independent activation of the androgen receptor by the differentiation agent butyrate in human prostate cancer cells.
    Sadar MD, Gleave ME.
    Cancer Res; 2000 Oct 15; 60(20):5825-31. PubMed ID: 11059779
    [Abstract] [Full Text] [Related]

  • 11. Enhanced androgen receptor signaling correlates with the androgen-refractory growth in a newly established MDA PCa 2b-hr human prostate cancer cell subline.
    Hara T, Nakamura K, Araki H, Kusaka M, Yamaoka M.
    Cancer Res; 2003 Sep 01; 63(17):5622-8. PubMed ID: 14500404
    [Abstract] [Full Text] [Related]

  • 12. Prosaposin upregulates AR and PSA expression and activity in prostate cancer cells (LNCaP).
    Koochekpour S, Lee TJ, Wang R, Culig Z, Delorme N, Caffey S, Marrero L, Aguirre J.
    Prostate; 2007 Feb 01; 67(2):178-89. PubMed ID: 17044040
    [Abstract] [Full Text] [Related]

  • 13. Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence.
    Unni E, Sun S, Nan B, McPhaul MJ, Cheskis B, Mancini MA, Marcelli M.
    Cancer Res; 2004 Oct 01; 64(19):7156-68. PubMed ID: 15466214
    [Abstract] [Full Text] [Related]

  • 14. Regulation of FGF8 expression by the androgen receptor in human prostate cancer.
    Gnanapragasam VJ, Robson CN, Neal DE, Leung HY.
    Oncogene; 2002 Aug 01; 21(33):5069-80. PubMed ID: 12140757
    [Abstract] [Full Text] [Related]

  • 15. Partial agonist/antagonist properties of androstenedione and 4-androsten-3beta,17beta-diol.
    Chen F, Knecht K, Leu C, Rutledge SJ, Scafonas A, Gambone C, Vogel R, Zhang H, Kasparcova V, Bai C, Harada S, Schmidt A, Reszka A, Freedman L.
    J Steroid Biochem Mol Biol; 2004 Aug 01; 91(4-5):247-57. PubMed ID: 15336702
    [Abstract] [Full Text] [Related]

  • 16. Hormonal regulation of beta2-adrenergic receptor level in prostate cancer.
    Ramberg H, Eide T, Krobert KA, Levy FO, Dizeyi N, Bjartell AS, Abrahamsson PA, Taskén KA.
    Prostate; 2008 Jul 01; 68(10):1133-42. PubMed ID: 18454446
    [Abstract] [Full Text] [Related]

  • 17. Prostate cancer cells (LNCaP) generated after long-term interleukin 6 (IL-6) treatment express IL-6 and acquire an IL-6 partially resistant phenotype.
    Hobisch A, Ramoner R, Fuchs D, Godoy-Tundidor S, Bartsch G, Klocker H, Culig Z.
    Clin Cancer Res; 2001 Sep 01; 7(9):2941-8. PubMed ID: 11555613
    [Abstract] [Full Text] [Related]

  • 18. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor.
    Culig Z, Hobisch A, Cronauer MV, Radmayr C, Trapman J, Hittmair A, Bartsch G, Klocker H.
    Cancer Res; 1994 Oct 15; 54(20):5474-8. PubMed ID: 7522959
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Androgen sensitivity related proteins in hormone-sensitive and hormone-insensitive prostate cancer cell lines treated by androgen antagonist bicalutamide.
    Madarová J, Lukesová M, Hlobilková A, Riháková P, Murray PG, Student V, Vojtsek B, Kolár Z.
    Neoplasma; 2001 Oct 15; 48(5):419-24. PubMed ID: 11845989
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 60.